SciencePower, a next-generation postbiotic platform company, today announced that it has entered into a license agreement with Mayo Clinic. The agreement enables collaborative research led by Mayo Clinic investigators to explore the potential of SciencePower’s proprietary postbiotic compositions in breast cancer biology. The collaboration will focus on understanding how specific microbiome-derived compositions influence immune and cellular pathways relevant to breast cancer. Early preclinical ...